Mid-Cap Pharma Stock Akum Drugs Rebounds 35% From April Loks: Should You Buy or Sell The Stock?

Stock Market Today: The Mid-Cap Pharma Stock Akum Drugs, Has Been Rebounding Well and Has Risen Almost 35% Since Closing Lows in April. Should you buy or sell the stock that has seen sharp gains? Here is what analysts say

Mid Cap Pharm Stock Akums Drugs Share Price movement

Akums Drugs and Pharmaceuticals Share Price Has Seen Sharp Gains of Almost 35% From Closing Lows of Around 421 seen on the bse on 7 April 2025 to 568 levels now. The Akums Drugs and Pharmaceuticals Share Price Earlier Had Seen Sharp Correction, Hitting 52 Week Lows of 407.40 on 7 April 2025, Inline with Sharp Correction in the Markets Following Global UncertainTies and Trump Tarifs

Mid-cap stock akums drugs and pharmaceuticals- analysts views

ICICI Securities Post Q4 FY25 Results Recently Had Said That Akums Drugs and Pharmaceuticals’ (Akums) Q4Fy25 Revenue was ahead of our expectation, thugh unfavorable project mix Margins. The CDMO Business or Contract Development and Manufacturing Business Grew A Strong 14.8% in Q4 LED by Volume Growth and Realization Improvement. They also mentioned that akums have 1500 Crore in Cash on Hand, which it may use to expand its expenses and CDMO Operations and Add New Capabilites. In Q4Fy27 Supplies for a New 5-Year Export Order for a European client are expected to start.

The Management Expects 8–10% Rise in the CDMO, Akuentis, and API segments, with experts expected to grow at a great at a greats of 20% in fy26, highlighted icici analysts. As per is it also also plans to curtail losses in trade generals segment and up to 50% reduction in loss ( 44 Crore Loss in FY25) In API Segment in FY26. ICICI security 710.

Mid-cap stock akums drugs and pharmaceuticals-technical views

Akums is forming a rounding bottom on the daily charts, having reclaimed its daily moving average. The recent pullback successfully tested these rising average, signaling underling strength. A breakout above 600 will likely trigger fresh bulish momentum, initially targeting the 700- 750 zone. The Strong Base Formation Combined with Supportive Moving Average Sugges The Stock is Well-Positioned for an upside continuration on the breaking the breeded, said anshul jain, always live Lakshmishree investments

Disclaimer: The views and recommendations made about individual analysts or broking companies, and not of Mint. We Advise Investors to Check With Certified Experts Before Making Any Investments Decisions.